Recent results from Johnson & Johnson's MonumenTAL-3 study reveal that the combination of TALVEY® (talquetamab) and daratumumab may significantly improve treatment outcomes for patients with relapsed or refractory multiple myeloma (RRMM).
Breakthrough Findings in Myeloma Treatment
The impressive results from this study point to the promise of talquetamab plus daratumumab as a potential new bispecific combination for patients with relapsed or refractory multiple myeloma.
Peter Voorhees, M.D., Professor of Hematology and Oncology
- Progression-free survival (PFS) up to 81.3% at 24 months.
- Overall survival (OS) rate of 89.2% at 24 months.
The study demonstrated a 72.0% reduction in the risk of disease progression or death and a 53.0% decrease in the risk of death compared to standard treatment regimens. These results were presented at the 2026 European Hematology Association Annual Meeting.
MonumenTAL-3 is particularly notable as it represents the first Phase 3 trial to show the effectiveness of a GPRC5D bispecific antibody in earlier lines of treatment for myeloma. Johnson & Johnson has positioned itself as a leader in this space by advancing bispecific therapies.
The trial involved 864 participants who had previously undergone at least one line of therapy, with a majority being refractory to lenalidomide and other treatments. The combination showed improvements across various endpoints, including overall response rates and complete response rates.
Experts emphasize the importance of these findings in providing new options tailored to patients' specific needs at critical stages of their treatment journey.
As the treatment landscape for RRMM evolves, Johnson & Johnson is actively working with regulatory authorities to expedite access to these innovative therapies for patients worldwide.